FDA 483 - Amgen Inc. - November 30, 2023

Amgen Inc. in New Albany, OH, underwent an FDA inspection focusing on assembly, labeling, packaging, and release testing. The inspection revealed a significant observation where the firm failed to retain sufficient reserve samples of drug product to perform all required release tests for products like Repatha and Enbrel. This indicates a deficiency in quality control and adherence to sampling procedures.